Clinical Trials Logo

Clinical Trial Summary

This Phase III clinical study is to test efficacy, safety and pharmacokinetics of BT595 in treating patients with Primary Immunodeficiency (PID)


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02810444
Study type Interventional
Source Biotest
Contact
Status Completed
Phase Phase 3
Start date October 4, 2016
Completion date April 1, 2020

See also
  Status Clinical Trial Phase
Recruiting NCT03677557 - Safety, Tolerability, Patient Satisfaction and Cost of 16.5% Subcutaneous Immunoglobulin (Cutaquig®) Treatment Phase 4
Enrolling by invitation NCT01150240 - Clinical and Laboratory Online Patient- and Research Database for Primary Immunodeficiencies in Switzerland N/A
Recruiting NCT04944979 - Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Pediatric PID Patients (KIDCARES10) Phase 3
Completed NCT02627300 - Study of Octanorm Subcutaneous IG in Patients With Primary Immunodeficiency Diseases Who Have Completed the SCGAM-01 Trial Phase 3
Not yet recruiting NCT03252548 - Pediatric Primary Immunodeficiency Disease (PID) in China N/A
Completed NCT03961009 - Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in PID Patients Phase 3
Completed NCT04842643 - An Extension Study of TAK-664 for Japanese People With Primary Immunodeficiency Disease Phase 3
Not yet recruiting NCT06089122 - Efficacy, Safety, and Pharmacokinetics of Shu Yang IVIG Phase 3
Not yet recruiting NCT06150833 - Efficacy and Safety and Pharmacokinetics of Boya IVIG Phase 3